Advertisement

Topics

Apic Bio Launches to Advance First-in-Class Gene Therapy for Treatment of Alpha-1 Antitrypsin Deficiency (Alpha 1)

10:30 EDT 22 Aug 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
--The Alpha-1 Project (TAP) leads syndicate of investors for seed round financing Apic Bio, Inc., a pre-clinical stage gene therapy company leveraging its proprietary platform to advance therapies to treat rare diseases with...

Other Sources for this Article

Media Contact:
Northwind Strategies
Larry Carpman, 617-338-6601
larry@northwindstrategies.com
or
Company Contact & More Information
Apic Bio, Inc.
John Reilly, MS, MBA
President & COO
info@apic-bio.com
www.apic-bio.com

NEXT ARTICLE

More From BioPortfolio on "Apic Bio Launches to Advance First-in-Class Gene Therapy for Treatment of Alpha-1 Antitrypsin Deficiency (Alpha 1)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...